🌎 From #Rio to communities around the world, #RethinkRebuildRise continues.
How are you taking the lessons from #AIDS2026 and turning them into action in your work and community?
📣 Share what you’re taking forward and help keep the momentum going: https://t.co/QBr5CsYjAM
We crave to play with you, and we'll ensure we never leave you
Feel our tongues trace your skin, our cocks piercing your cursed ass, filling you with our infernal seed as we chant unholy rites.⛧ 🦂☣️#HAILSATAN#HailPhallus#GAYPORN#chudai#GaySatanic#Satanic#COCKISGOD
When does silence become complicity?
Dr. Jeanne Marrazzo watched colleagues who knew exactly what was happening - grants canceled, clinical trial participants cut off from life-saving medications, an anti-vaccine agenda replacing decades of evidence - say nothing. Not because they didn't understand the consequences, but because they did.
She calls it anticipatory obedience.
Dr. Marrazzo was director of the NIAID - the NIH institute responsible for the majority of the world's infectious disease research — and she pushed back. She filed a whistleblower complaint and was fired three weeks later.
The infrastructure that made the United States the global leader in biomedical research is being dismantled in real time. Most of the people who could say something aren't saying it.
Dr. Marrazzo said it anyway. This is what it cost her - and what she wants you to know.
🎧 https://t.co/MwC0dWV1cc
#publichealth #NIH @DrJeanneM
Tasia Baldwin's work as a Seattle Vaccine Trials Unit Community Advisory Board member allows her to bring healing to many people — now and in years to come. The SVTU is a Fred Hutch-based program that focuses on preventive and observational HIV studies. https://t.co/kjeFRkx83G
New app alert: Vela (https://t.co/6uvz0IzXEP) is a modern dating platform built for people with STDs & chronic condition focused on privacy, face verification, and stigma-free connections. Still in early rollout (CA & Canada), aiming to make dating safer and more human.
👇👇
https://t.co/YvYdMfZzJX
The search for a way to control HIV without antiretroviral therapy continued to generate both promising signals and sobering setbacks at the recent Conference on Retroviruses and Opportunistic Infections. Here are five highlights. #CROI2026 https://t.co/SylFcMgfgR
New Podcast Available: Episode 71 - CROI 2026 Review: What’s New, What’s Next in HIV Research with Dr Peter Hunt (March 10, 2026) https://t.co/VV969mBAsH #IASUSA#CROI2026@CarlosdelRio@drmt
As more people live longer with HIV, managing other health conditions is increasingly important. Research presented at #CROI2026 covered a wide range of issues – from new obesity drugs and cardiovascular risk to transplant outcomes and stimulant drug use. https://t.co/hWoTegCGNA
🚨 BREAKING: Claude can now build your entire resume and LinkedIn profile like a $500/hour executive recruiter from Robert Half. For free.
Here are 12 prompts that get you interview calls within 7 days:
(Save this before it disappears)
Conflicting results highlight the challenge of an HSV vaccine: some trials showed strong protection in specific groups, while larger studies failed to prevent HSV-2 overall—revealing inconsistent efficacy depending on population and prior exposure. Science is still searching for a breakthrough.
https://t.co/FFAaImfOXV
🚨 BREAKING: Claude can now write legal contracts like NDAs, freelance agreements, and LLC paperwork better than $800/hour corporate lawyers.
Here are 12 prompts that replace $15,000 in legal bills:
(Save this before it disappears)
Moderna is reportedly pulling back on some vaccine programs—including STI research—amid regulatory uncertainty and funding cuts in the U.S.
Experts warn shifting policies could slow innovation and push vaccine development overseas.
This isn’t just about one company… it impacts the future of vaccines. 💉
https://t.co/PDpERbtGRV
A new study shows that HSV-1 infection behaves differently depending on the cell type infected. The timing of viral DNA replication, mRNA/protein production, and virus output varies across cells, and some cells rely more on the viral protein ICP27 for replication—highlighting how cellular context strongly shapes HSV-1 infection dynamics.
https://t.co/8IvPr5InpO
As of March 2026, several herpes vaccine and antiviral candidates are still being studied in clinical trials. These include new approaches like DNA, mRNA, subunit, and live-attenuated vaccines, but no HSV-1 or HSV-2 vaccine has been approved yet anywhere in the world. Research continues to address the global burden of herpes.
👇👇
https://t.co/Ww8EEMovM9
Could a two-drug combo simplify #HIV treatment? ARTISTRY-1 results are intriguing, but experts urge caution.
Dr. Benjamin Young and @BodyProHIV’s Myles Helfand explain: https://t.co/H5W9xXY1O4
#HIVCare#ART#HIVResearch
At #CROI2026, Peter Staley shared his journey from his 1985 AIDS diagnosis to ACT UP activism with Martin Delaney, fighting for early HIV drug access and forging the activist–scientist partnership that drove major breakthroughs. Watch it now on YouTube: https://t.co/rxQmR831Sf
New Podcast Available: Episode 70 - From Wall Street to ACT UP: A Life Rewritten by HIV with Peter Staley (February 27, 2026) https://t.co/tUoAaCvurQ #IASUSA#CROI2026@CarlosdelRio@drmt